Evidence supporting the use of: Ligandrol
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ligandrol (also known as LGD-4033) is a selective androgen receptor modulator (SARM) that has been investigated for its potential in treating muscle wasting and osteoporosis. The rationale for its use in osteoporosis lies in its anabolic effects on bone and muscle tissue by selectively binding to androgen receptors. Preclinical studies in animal models have demonstrated that LGD-4033 can increase bone mineral density and improve bone strength. Early phase clinical trials in humans have shown that Ligandrol increases lean body mass, which can indirectly benefit bone health by reducing fall risk, a key factor in osteoporotic fractures.

However, as of June 2024, there is limited direct clinical evidence supporting Ligandrol's use specifically for treating osteoporosis in humans. Most published research consists of small phase I or II trials focused on safety and muscle mass, with bone health effects inferred from surrogate markers rather than direct fracture or bone density outcomes. No large-scale, peer-reviewed phase III trials have established its efficacy or safety for osteoporosis, and it is not approved by regulatory agencies for this indication. Thus, while there is a scientific basis for investigating Ligandrol in osteoporosis, the clinical evidence remains preliminary and incomplete.

More about Ligandrol
More about Osteoporosis

Products containing Ligandrol

We currently have no products on Vitabase that contain this ingredient.